1734 TAI Week ended 07 Aug 2026

Weekly Investor Report

Sinphar Pharmaceutical Co.,Ltd. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 31.80 TWD
0.3% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 10.0% above the Trend Line and sits at 91.1% of its 52-week range. The latest completed week returned 0.3%, after a 5.3% four-week move. The latest news-sentiment score is 50/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal.

Setup score 55 out of 100
Latest Close 31.80 TWD 7 Aug 2026
1W Return 0.3% latest completed week
4W Return 5.3% short-term follow-through
12W Return 13.9% quarterly tape
Trend Breadth 65.4% 34 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 9-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • No major top-level risk cluster is currently dominant.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.3% Latest completed week; four-week move 5.3%. Indicator stack 67/74 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 50/100 1 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 10.0% above the Trend Line and sits at 91.1% of its 52-week range. The latest completed week returned 0.3%, after a 5.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8912-week average 0.71

12-week confirmation

Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.89Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 5.3% over four weeks, 13.9% over 12 weeks, and 14.6% over one year. The current trend has remained active for 9 consecutive weeks.

Performance by holding period

1W0.3%
4W5.3%
12W13.9%
26W12.2%
52W14.6%
Active trend streak9 weeks
Active weeks in one year34
Trend breadth65.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.20Latest activity-pressure read.
Pressure change28.7%Four-week change in activity pressure.
Leadership-19.11Latest relative-leadership reading.
RS change31.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

A published fundamentals and factor snapshot is not available for this company.

Open full factor analysis

No published fundamental snapshot is available for this company.

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 1 relevant articles.

0 positive · 1 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-1.4%Distance below the 52-week high.
13-week volatility2.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 269 weeks finished lower.
Best week+6.7%Week of 24 Jul.
Worst week-2.7%Week of 8 May.
Latest week+0.3%Week of 7 Aug.

Shape of recent returns

Strong gains2
Modest gains14
Flat weeks1
Modest losses9
Sharp losses0
Recent vol2.4%13-week weekly-return volatility.
Base vol1.8%52-week weekly-return volatility.
Up/down split27/21Count of positive and negative weeks in the 52-week window.
Average skew1.4% / -1.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape53/100

Trend, activity pressure, participation, and risk combine to a 53/100 tape read.

 Indicator analysis59/100

Latest 12-week confirmation: trend 9/12, activity pressure 9/12, relative leadership 0/12.

Activity pressure 0.89; No reversal markers Factors50/100

No published factor snapshot is available yet.

 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 1 relevant articles.

Sinphar Pharmaceutical Co. Ltd.實際值與預估值(TWSE:1734) Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202631.80 TWD0.3%28.90 TWD27.19 TWD1.20-19.111.1MOn
31 Jul 202631.70 TWD1.0%28.77 TWD27.14 TWD1.24-18.122.1MOn
24 Jul 202631.40 TWD6.7%28.64 TWD27.09 TWD1.24-20.633.3MOn
17 Jul 202629.43 TWD-2.6%28.52 TWD27.05 TWD1.06-24.612.2MOn
10 Jul 202630.21 TWD-1.5%28.47 TWD27.02 TWD0.93-27.992.3MOn
3 Jul 202630.67 TWD5.0%28.40 TWD27.00 TWD0.62-29.942.2MOn
26 Jun 202629.21 TWD0.3%28.32 TWD26.98 TWD0.38-30.772.2MOn
19 Jun 202629.11 TWD1.3%28.28 TWD26.97 TWD0.14-34.571.3MOn
12 Jun 202628.75 TWD0.2%28.25 TWD26.96 TWD0.01-32.861.8MOn
5 Jun 202628.70 TWD2.4%28.26 TWD26.94 TWD-0.04-35.112.9MOff
29 May 202628.02 TWD-0.2%28.28 TWD26.92 TWD-0.20-37.002.3MOff
22 May 202628.06 TWD0.5%28.31 TWD26.89 TWD-0.06-34.071.7MOff
15 May 202627.93 TWD-0.2%28.35 TWD26.86 TWD0.33-33.412.2MOff
8 May 202627.97 TWD-2.7%28.34 TWD26.84 TWD0.73-34.741.7MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context